FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3176106133> ?p ?o ?g. }

• W3176106133 endingPage "1302" @default.
• W3176106133 startingPage "1302" @default.
• W3176106133 abstract "<h3>Importance</h3> Paraneoplastic neurological syndromes are associated with neuronal autoantibodies, and some of these autoantibodies are associated with neuropsychological symptoms. The most common underlying tumor is lung cancer. The association of neuronal autoantibodies with cognitive deficits has not been systematically investigated in patients with small cell lung cancer (SCLC) and non–small cell lung cancer (NSCLC). <h3>Objective</h3> To assess the frequency of neuronal autoantibodies in patients with lung cancer and analyze their association with cognitive function. <h3>Design, Setting, and Participants</h3> This prospective, cross-sectional study included 167 patients with lung cancer (both SCLC and NSCLC) recruited at a single lung cancer center in Berlin, Germany, between June 2015 and April 2016. Detailed neuropsychological testing was performed in a carefully selected subgroup of 97 patients (from which patients with potential confounding factors were excluded). Investigators were blinded to patients’ autoantibody status and cognitive test results. Data were analyzed from May 2016 to December 2019. <h3>Main Outcomes and Measures</h3> Prevalence of neuronal autoantibodies and their association with cognitive impairment. The evaluation of autoantibodies as potential risk factors for cognitive impairment was performed using bayesian logistic regression models. <h3>Results</h3> Among 167 patients with lung cancer (median age, 66.0 years [interquartile range, 59.0-72.0 years]; 105 men [62.9%]), 127 had NSCLC, and 40 had SCLC. Brain-directed autoantibodies were detected in 61 of 167 patients (36.5%); 33 patients (19.8%) had known autoantibodies and 28 patients (16.8%) had autoantibodies against currently unknown antigens that were detected through immunohistochemical analysis. Cognitive impairment was found in 65 of 97 patients (67.0%). Among patients with SCLC, the odds of cognitive impairment for those with any autoantibodies was 11-fold higher (odds ratio [OR], 11.0; 95% credible interval [CrI], 1.2-103.6) than that of autoantibody-negative patients, and the increased odds were independent of age, sex, and neurological deficit. Among patients with NSCLC, those with immunoglobin A autoantibodies targeting the<i>N</i>-methyl-d-aspartate receptor had a relevantly increased odds of verbal memory deficits (OR, 182.8; 95% CrI, 3.1-10 852.4). Autoantibodies against currently unknown antigens were also associated with increased odds of cognitive impairment (OR, 2.8; 95% CrI, 0.6-12.1). <h3>Conclusions and Relevance</h3> In this prospective, cross-sectional study, more than one-third of patients with lung cancer had neuronal autoantibodies that were found to be associated with cognitive impairment. These autoantibodies might represent a potentially treatable mechanism of immune-mediated cognitive impairment among patients with lung cancer." @default.
• W3176106133 created "2021-07-05" @default.
• W3176106133 creator A5007624283 @default.
• W3176106133 creator A5012840376 @default.
• W3176106133 creator A5029295924 @default.
• W3176106133 creator A5035898499 @default.
• W3176106133 creator A5037763117 @default.
• W3176106133 creator A5049373092 @default.
• W3176106133 creator A5055759380 @default.
• W3176106133 creator A5076424779 @default.
• W3176106133 creator A5082092472 @default.
• W3176106133 date "2021-09-01" @default.
• W3176106133 modified "2023-10-18" @default.
• W3176106133 title "Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer" @default.
• W3176106133 cites W1910892799 @default.
• W3176106133 cites W1935161565 @default.
• W3176106133 cites W1980325803 @default.
• W3176106133 cites W2014266239 @default.
• W3176106133 cites W2016421065 @default.
• W3176106133 cites W2025388062 @default.
• W3176106133 cites W2045623946 @default.
• W3176106133 cites W2052498273 @default.
• W3176106133 cites W2053734674 @default.
• W3176106133 cites W2055500800 @default.
• W3176106133 cites W2056804370 @default.
• W3176106133 cites W2066039469 @default.
• W3176106133 cites W2112382743 @default.
• W3176106133 cites W2120325372 @default.
• W3176106133 cites W2124472369 @default.
• W3176106133 cites W2137119609 @default.
• W3176106133 cites W2137591261 @default.
• W3176106133 cites W2144683025 @default.
• W3176106133 cites W2159289827 @default.
• W3176106133 cites W2161594710 @default.
• W3176106133 cites W2506661329 @default.
• W3176106133 cites W2623549309 @default.
• W3176106133 cites W2742724396 @default.
• W3176106133 cites W2887771832 @default.
• W3176106133 cites W2922462565 @default.
• W3176106133 cites W2956177188 @default.
• W3176106133 cites W3106333376 @default.
• W3176106133 cites W4212867045 @default.
• W3176106133 cites W4255087266 @default.
• W3176106133 doi "https://doi.org/10.1001/jamaoncol.2021.2049" @default.
• W3176106133 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8251651" @default.
• W3176106133 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34196651" @default.
• W3176106133 hasPublicationYear "2021" @default.
• W3176106133 type Work @default.
• W3176106133 sameAs 3176106133 @default.
• W3176106133 citedByCount "10" @default.
• W3176106133 countsByYear W31761061332022 @default.
• W3176106133 countsByYear W31761061332023 @default.
• W3176106133 crossrefType "journal-article" @default.
• W3176106133 hasAuthorship W3176106133A5007624283 @default.
• W3176106133 hasAuthorship W3176106133A5012840376 @default.
• W3176106133 hasAuthorship W3176106133A5029295924 @default.
• W3176106133 hasAuthorship W3176106133A5035898499 @default.
• W3176106133 hasAuthorship W3176106133A5037763117 @default.
• W3176106133 hasAuthorship W3176106133A5049373092 @default.
• W3176106133 hasAuthorship W3176106133A5055759380 @default.
• W3176106133 hasAuthorship W3176106133A5076424779 @default.
• W3176106133 hasAuthorship W3176106133A5082092472 @default.
• W3176106133 hasBestOaLocation W31761061331 @default.
• W3176106133 hasConcept C119060515 @default.
• W3176106133 hasConcept C121608353 @default.
• W3176106133 hasConcept C126322002 @default.
• W3176106133 hasConcept C143998085 @default.
• W3176106133 hasConcept C159654299 @default.
• W3176106133 hasConcept C163764329 @default.
• W3176106133 hasConcept C203014093 @default.
• W3176106133 hasConcept C2776256026 @default.
• W3176106133 hasConcept C71924100 @default.
• W3176106133 hasConceptScore W3176106133C119060515 @default.
• W3176106133 hasConceptScore W3176106133C121608353 @default.
• W3176106133 hasConceptScore W3176106133C126322002 @default.
• W3176106133 hasConceptScore W3176106133C143998085 @default.
• W3176106133 hasConceptScore W3176106133C159654299 @default.
• W3176106133 hasConceptScore W3176106133C163764329 @default.
• W3176106133 hasConceptScore W3176106133C203014093 @default.
• W3176106133 hasConceptScore W3176106133C2776256026 @default.
• W3176106133 hasConceptScore W3176106133C71924100 @default.
• W3176106133 hasIssue "9" @default.
• W3176106133 hasLocation W31761061331 @default.
• W3176106133 hasLocation W31761061332 @default.
• W3176106133 hasLocation W31761061333 @default.
• W3176106133 hasOpenAccess W3176106133 @default.
• W3176106133 hasPrimaryLocation W31761061331 @default.
• W3176106133 hasRelatedWork W2032912323 @default.
• W3176106133 hasRelatedWork W2061253854 @default.
• W3176106133 hasRelatedWork W2135221496 @default.
• W3176106133 hasRelatedWork W2390152934 @default.
• W3176106133 hasRelatedWork W2754890083 @default.
• W3176106133 hasRelatedWork W2971392718 @default.
• W3176106133 hasRelatedWork W3022881879 @default.
• W3176106133 hasRelatedWork W3037686638 @default.
• W3176106133 hasRelatedWork W3162511055 @default.
• W3176106133 hasRelatedWork W4252135025 @default.
• W3176106133 hasVolume "7" @default.

• next